A citation-based method for searching scientific literature




Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu-Chou Su, Jhanelle E Gray, Siow-Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S Ramalingam. N Engl J Med 2018
Times Cited: 2057




List of shared articles



Times cited


Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.
Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago-Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer-Meir Salame,[...]. EMBO Mol Med 2021
5


Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.
Nir Peled, Waleed Kian, Edna Inbar, Iris M Goldstein, Melanie Zemel, Ofer Rotem, Anna B Rozenblum, Hovav Nechushtan, Elizabeth Dudnik, Daniel Levin,[...]. Neurooncol Adv 2021
0

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
Yung-Hung Luo, Han Liu, Jason A Wampfler, Henry D Tazelaar, Yalun Li, Tobias Peikert, Dan Liu, Konstantinos Leventakos, Yuh-Min Chen, Yanan Yang,[...]. J Cancer Res Clin Oncol 2021
0

A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
Steffen Grann Jensen, Samantha Epistolio, Cesilie Lind Madsen, Majbritt Hauge Kyneb, Alice Riva, Alessia Paganotti, Jessica Barizzi, Rasmus Koefoed Petersen, Michael Børgesen, Francesca Molinari,[...]. PLoS One 2021
2

Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.
Julia Roeper, Sylke Kurz, Christian Grohé, Frank Griesinger. Future Oncol 2021
6




Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy.
Qiaoyou Weng, Junguo Hui, Hailin Wang, Chuanqiang Lan, Jiansheng Huang, Chun Zhao, Liyun Zheng, Shiji Fang, Minjiang Chen, Chenying Lu,[...]. Front Oncol 2021
4

Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Yosuke Miyashita, Ryo Ko, Naoko Shimada, Yoichiro Mitsuishi, Keita Miura, Naohisa Matsumoto, Tetsuhiko Asao, Takehito Shukuya, Rina Shibayama, Ryo Koyama,[...]. Thorac Cancer 2021
0



Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
Matin Shaikh, Yashodeep Shinde, Rahul Pawara, Malleshappa Noolvi, Sanjay Surana, Iqrar Ahmad, Harun Patel. J Med Chem 2022
3

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.
Umberto Malapelle, Sara Pilotto, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Luisella Righi, Angela Listì, Paolo Bironzo, Lorenzo Belluomini, Fabrizio Tabbò,[...]. Crit Rev Oncol Hematol 2021
1

EGFR signaling pathway as therapeutic target in human cancers.
Elena Levantini, Giorgia Maroni, Marzia Del Re, Daniel G Tenen. Semin Cancer Biol 2022
0

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Carlo Genova, Giovanni Rossi, Marco Tagliamento, Erika Rijavec, Federica Biello, Luigi Cerbone, Lodovica Zullo, Francesco Grossi. Expert Rev Respir Med 2020
11